The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α

Journal of Clinical Medicine

VanceB. Matthews¹  LakshiniY. Herat¹  MárcioG. Kiuchi²  MarkusP. Schlaich²  AaronL. Magno³  NatalieC. Ward⁴ 

[1] Dobney Hypertension Centre, School of Biomedical Science—Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia;Dobney Hypertension Centre, School of Medicine—Royal Perth Hospital Unit, University of Western Australia, Crawley, WA 6009, Australia;Research Centre, Royal Perth Hospital, Perth, WA 6000, Australia;School of Public Health, Curtin University, Perth, WA 6102, Australia;

关键词: human;    hypertension;    short chain fatty acids;    FGF21;    TNFSF14;    TNF-α;   

DOI  :  10.3390/jcm9092764

来源: DOAJ

【 摘 要 】

Studying the role of circulatory factors in the pathogenesis of diseases has been key to the development of effective therapies. We sought to examine the effect of antihypertensive therapies on numerous circulatory factors including short chain fatty acids and growth factors in a human cohort. A subset of participants from an earlier study was characterized by their hypertensive and/or treatment status and separated into three groups: (i) normotensives; (ii) untreated hypertensive and (iii) treated hypertensive subjects. Circulating levels of short chain fatty acids, FGF21 and TNF superfamily members were measured as part of this study. Both F2-isoprostane and circulating lipid levels were reanalysed as part of this current study. We found that antihypertensive treatment increased butyrate levels and decreased acetate levels to levels similar to normotensives. We also found that antihypertensive treatments reduced levels of circulating FGF21, TNFSF14 and TNF-α. In conclusion, we identified several circulatory factors that are altered in hypertension.

【 授权许可】

Unknown